SG11201806166WA - Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds - Google Patents
Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compoundsInfo
- Publication number
- SG11201806166WA SG11201806166WA SG11201806166WA SG11201806166WA SG11201806166WA SG 11201806166W A SG11201806166W A SG 11201806166WA SG 11201806166W A SG11201806166W A SG 11201806166WA SG 11201806166W A SG11201806166W A SG 11201806166WA SG 11201806166W A SG11201806166W A SG 11201806166WA
- Authority
- SG
- Singapore
- Prior art keywords
- alderley
- mereside
- cheshire
- block
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1602241.0A GB201602241D0 (en) | 2016-02-08 | 2016-02-08 | Antibacterial compounds |
GBGB1616460.0A GB201616460D0 (en) | 2016-09-28 | 2016-09-28 | Antibacterial compounds |
PCT/GB2017/050318 WO2017137744A1 (en) | 2016-02-08 | 2017-02-08 | Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806166WA true SG11201806166WA (en) | 2018-08-30 |
Family
ID=58046706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806166WA SG11201806166WA (en) | 2016-02-08 | 2017-02-08 | Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds |
Country Status (11)
Country | Link |
---|---|
US (1) | US10487093B2 (ja) |
EP (1) | EP3413976A1 (ja) |
JP (1) | JP2019504850A (ja) |
KR (1) | KR20180108781A (ja) |
CN (1) | CN109121397A (ja) |
AU (1) | AU2017218556A1 (ja) |
BR (1) | BR112018016208A2 (ja) |
CA (1) | CA3012583A1 (ja) |
EA (1) | EA201891654A1 (ja) |
SG (1) | SG11201806166WA (ja) |
WO (1) | WO2017137744A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111171020A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005030733A1 (de) * | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
CL2008001003A1 (es) * | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
RU2501799C2 (ru) * | 2008-02-22 | 2013-12-20 | Актелион Фармасьютикалз Лтд | Поизводные оксазолидинона |
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
JP2014525396A (ja) | 2011-08-11 | 2014-09-29 | アクテリオン ファーマシューティカルズ リミテッド | キナゾリン−2,4−ジオン誘導体 |
IN2014CN04126A (ja) * | 2011-11-08 | 2015-07-10 | Actelion Pharmaceuticals Ltd | |
CN103958525A (zh) * | 2011-11-30 | 2014-07-30 | 埃科特莱茵药品有限公司 | 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素 |
-
2017
- 2017-02-08 JP JP2018541259A patent/JP2019504850A/ja active Pending
- 2017-02-08 CA CA3012583A patent/CA3012583A1/en not_active Abandoned
- 2017-02-08 EP EP17705463.2A patent/EP3413976A1/en not_active Withdrawn
- 2017-02-08 SG SG11201806166WA patent/SG11201806166WA/en unknown
- 2017-02-08 EA EA201891654A patent/EA201891654A1/ru unknown
- 2017-02-08 AU AU2017218556A patent/AU2017218556A1/en not_active Abandoned
- 2017-02-08 WO PCT/GB2017/050318 patent/WO2017137744A1/en active Application Filing
- 2017-02-08 BR BR112018016208A patent/BR112018016208A2/pt not_active Application Discontinuation
- 2017-02-08 US US16/074,904 patent/US10487093B2/en not_active Expired - Fee Related
- 2017-02-08 KR KR1020187025425A patent/KR20180108781A/ko unknown
- 2017-02-08 CN CN201780022513.4A patent/CN109121397A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017218556A1 (en) | 2018-08-09 |
US10487093B2 (en) | 2019-11-26 |
CN109121397A (zh) | 2019-01-01 |
EP3413976A1 (en) | 2018-12-19 |
EA201891654A1 (ru) | 2019-01-31 |
CA3012583A1 (en) | 2017-08-17 |
BR112018016208A2 (pt) | 2018-12-18 |
WO2017137744A1 (en) | 2017-08-17 |
KR20180108781A (ko) | 2018-10-04 |
US20190055266A1 (en) | 2019-02-21 |
JP2019504850A (ja) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201804934PA (en) | Novel Compounds | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201408123SA (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |